Ness Tsiona-based Foamix, a developer of topical foam delivery systems for dermatology and other applications, said Monday it licensed its new lice treatment product PerFoam 1% to Taro Pharmaceutical Industries. Foamix will transfer technology to Haifa-based Taro, which will upscale, manufacture, register and commercialize PerFoam 1% for distribution in Israel and the Palestinian territories. The companies did say what the deal was worth. The product is scheduled to be launched in late 2008.